HC Wainwright Rates Achieve Life Sciences (ACHV) buy

HC Wainwright maintains a buy rating on ACHV with a $12 price target, a 126.84% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 12:02 PM EDT · Updated Jun 22, 2026, 9:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Achieve Life Sciences, Inc. ($ACHV) "buy" with a $12 price target on June 22, 2026.

Since the rating, $ACHV is up 22.2% after 1 week, up 23.7% after 1 month and up 25.1% to date (from the $5.10 close on Jun 22, 2026).

ACHV Achieve Life Sciences, Inc.

$6.38 +28.37% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating on ACHV, maintaining a price target of $12.
HC Wainwright's $12 price target implies 126.84% upside from Achieve Life Sciences, Inc.'s ($ACHV) current $5.29 share price.
ACHV shares traded at $5.29 on Monday, reflecting ongoing interest from analysts.
Peer funds like Vanguard Capital Management opened new positions in ACHV, showing varied institutional activity.

Get $ACHV trade alerts by text

We text you when insiders, Congress or big funds trade $ACHV. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Achieve Life Sciences, Inc. alert may contain errors. Disclosures

HC Wainwright has reaffirmed its buy rating on ACHV, setting a price target of $12 as of June 22, 2026. This reiteration comes as part of their ongoing analysis of the company.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +53.16% hypothetical

All-time return +154.98% S&P 500 +28.67%

vs. S&P 500 +126.31% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

On June 22, 2026, HC Wainwright & Co. reiterated its buy rating for ACHV with a price target of $12. Earlier, on April 21, 2026, Canaccord Genuity initiated coverage with a buy rating and a $13 target. These ratings underscore the continued interest in ACHV from analysts.

Other Institutional Activity in ACHV

Vanguard Capital Management LLC opened a new position in ACHV, acquiring 2,204,714 shares valued at approximately $6.48 million. Meanwhile, Millennium Management LLC reduced its holdings by 281,778 shares, now holding 1,077,338 shares worth about $3.17 million. Other funds like Franklin Resources Inc. and Simplify Asset Management Inc. maintained their positions without any changes.

Insider Buying and Selling at Achieve Life Sciences, Inc.

Recent insider activity at ACHV includes significant buying by key personnel. On May 29, 2026, insiders Waldman Reid Alexander and Jeffrey Farrow each purchased 47,250 shares. Earlier, on April 18, 2026, CEO and President Andrew Goldberg made multiple purchases, including 11,706,270 shares.

Bottom Line

HC Wainwright's reiterated buy rating and $12 price target reflect a positive outlook for ACHV. With varied institutional activity and insider buying, the company remains a focal point for investors. Remember, 13F filings and analyst ratings are backward-looking and may not represent the most current positions or sentiments.

12-month forecast

$ACHV price target

Achieve Life Sciences, Inc. daily closes and this analyst's $12 target. Not advice.

More on this

Source: HC Wainwright's rating change on $ACHV (Jun 22, 2026). Written by software, not financial advice. How we make alerts